Endocrine Abstracts

Introduction: Clinical trial data demonstrate improved glycemic control in individuals with type 1 diabetes (T1D),especially, reduction of time in hypoglycaemia with flash glucose monitoring (FGM);however real-life conditions can modify this scenario.Aim: To examine real world use and glycemic control following a standardized initiation process of FGM.Methods: Individuals aged 18 years or older with T1D were prospectively recruited...

Introduction Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab treatment, Graves' disease being the most prevalent manifestation. To date, thyroid autoimmunity events have not been reported with CD20 targeting monoclonal a...